• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pfizer cuts 15 R&D projects, buys King

Pfizer cuts 15 R&D projects, buys King

March 2, 2011
CenterWatch Staff

Pfizer has cut its R&D pipeline again, removing 15 experimental projects in a bid to restructure its operations and conserve earnings, according to PharmaTimes. 

Projects being eliminated span early- to late-stage trials, including Lyrica (pregabalin) for generalized anxiety disorder. Three phase III projects were cut: apixaban for acute coronary syndrome, Thelin (sitaxentan) for pulmonary arterial hypertension and Lyrica (pregabalin) for post-operative pain. These cuts follow an earlier cut of its R&D pipeline last year, when Pfizer said no less than 31 projects had to end to help it leverage its best assets and maximize efficiency.

Pfizer also announced the completion of its $3.6 billion purchase of King Pharmaceuticals. The deal provides access to King’s Meridian auto-injector business for emergency drug delivery, which develops and manufactures the EpiPen, as well as its Alpharma animal health business.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing